Hypofractionated IMRT for Prostate Cancer: A Feasibility Study
Author Information
Author(s): Junius Sara, Haustermans Karin, Bussels Barbara, Oyen Raymond, Vanstraelen Bianca, Depuydt Tom, Verstraete Jan, Joniau Steven, Van Poppel Hendrik
Primary Institution: University Hospital Gasthuisberg, Leuven, Belgium
Hypothesis
To assess the acute and late toxicity, quality of life, and failure rates of a hypofractionated IMRT schedule for prostate cancer.
Conclusion
The hypofractionated IMRT schedule for prostate cancer did not result in severe acute side effects, and late toxicities appeared acceptable.
Supporting Evidence
- None of the patients experienced grade III-IV toxicity.
- 10% had no acute genito-urinary toxicity, while 63% had grade I and 26% had grade II.
- Maximum acute gastrointestinal scores were 37% grade 0, 47% grade I, and 16% grade II.
- Grade II rectal bleeding peaked at 18% at 16 months but was 0% at 24-36 months.
- Quality of life urinary symptom scores normalized 6 months after treatment.
Takeaway
Doctors tested a new way to give radiation to men with prostate cancer, and it didn't cause serious side effects right away.
Methodology
38 men with localized prostate cancer received 66 Gy in 25 fractions using IMRT, with toxicity evaluated during and after treatment.
Limitations
The study had a relatively short follow-up period of 20 months, which may not capture long-term effects.
Participant Demographics
Mean age was 71 years, with a range of 54 to 79 years; 31 out of 38 patients received hormonal treatment.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website